| Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter’s transformation ZA Hing, JS Walker, EC Whipp, L Brinton, M Cannon, P Zhang, S Sher, ... Nature Communications 14 (1), 97, 2023 | 13 | 2023 |
| Radiant star nanoparticle prodrugs for the treatment of intracellular alveolar infections D Das, S Srinivasan, FD Brown, FY Su, AL Burrell, JM Kollman, A Postma, ... Polymer Chemistry 9 (16), 2134-2146, 2018 | 12 | 2018 |
| Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma SL Sloan, KA Renaldo, M Long, JH Chung, LE Courtney, K Shilo, ... PloS one 16 (5), e0250839, 2021 | 10 | 2021 |
| PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma SL Sloan, F Brown, M Long, C Weigel, S Koirala, JH Chung, B Pray, ... Blood 142 (10), 887-902, 2023 | 7 | 2023 |
| Targeting prmt5 to circumvent acquired ibrutinib resistance in mantle cell lymphoma S Sloan, F Brown, JH Chung, A Prouty, E Wheeler, BK Harrington, ... Blood 134, 4065, 2019 | 5 | 2019 |
| PRMT5 inhibition drives therapeutic vulnerability to combination treatment with BCL-2 inhibition in mantle cell lymphoma F Brown-Burke, I Hwang, S Sloan, C Hinterschied, JB Helmig-Mason, ... Blood Advances 7 (20), 6211-6224, 2023 | 3 | 2023 |
| PRMT5 Inhibition Reduces Autoinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis P Shindiapina, R Saadey, A Yasin, C Mao, A Wandke, EH Ahmed, ... Blood 140 (Supplement 1), 36-37, 2022 | 2 | 2022 |
| PRMT5 inhibition promotes FOXO1 tumor suppressor activity to drive a pro-apoptotic program that creates vulnerability to combination treatment with venetoclax in mantle cell … F Brown, I Hwang, S Sloan, C Hinterschied, JB Helmig-Mason, M Long, ... Blood 138, 681, 2021 | 2 | 2021 |
| PRMT5 inhibition modulates E2F1 and P53 to restore cell cycle regulation and drive DNA damage response in ibrutinib-resistant mantle cell lymphoma S Sloan, F Brown, M Long, JB Helmig-Mason, S Beck, JH Chung, ... Blood 138, 787, 2021 | 2 | 2021 |
| PRMT5 inhibition drives therapeutic vulnerability to BCL-2 inhibition with Venetoclax and provides rationale for combination therapy in mantle cell lymphoma F Brown, Y Zhang, C Hinterschied, A Prouty, S Sloan, JB Helmig-Mason, ... Blood 134, 302, 2019 | 2 | 2019 |
| Acquired resistance to PRMT5 inhibition in mantle cell lymphoma is associated with compensatory activation of multiple signaling pathways M Long, S Koirala, S Sloan, F Brown, S Tallada, C Hinterschied, K Corps, ... Blood 140 (Supplement 1), 3103-3104, 2022 | 1 | 2022 |
| Constitutive PRMT5 Expression Drives Spontaneous Lymphoblastic Lymphoma In Vivo L Villagomez, P Smith, F Yan, V Chen, S Sloan, JT Patton, M Long, ... Blood 140 (Supplement 1), 6381-6382, 2022 | | 2022 |
| Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma E Whipp, ZA Hing, JS Walker, S Sher, CB Cempre, F Brown, C Agostinelli, ... Blood 140 (Supplement 1), 8746-8747, 2022 | | 2022 |
| PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease EH Ahmed, C Weigel, R Saadey, E Brooks, T Cash, C Mao, A Yasin, ... Blood 140 (Supplement 1), 3116-3117, 2022 | | 2022 |
| PRMT5 inhibition alters mitochondrial dynamics in mantle cell lymphoma, creating vulnerability to BH3 mimetic compounds C Hinterschied, F Brown, J Ravikrishnan, JB Helmig-Mason, K Vaddi, ... Cancer Research 82 (12_Supplement), 1031-1031, 2022 | | 2022 |
| P1250: EU-SOX11CCND1: A NOVEL IMMUNOCOMPETENT MURINE MODEL OF MANTLE CELL LYMPHOMA F Brown, S Sloan, J Helmig-Mason, C Hinterschied, M Long, WK Chan, ... HemaSphere 6, 1135-1136, 2022 | | 2022 |
Youssef YoussefThe Ohio State UniversityVerified email at osumc.edu
